BridgeBio Oncology Therapeutics, Inc. 8-K

What Happened
BridgeBio Oncology Therapeutics, Inc. filed a Current Report on Form 8-K on January 7, 2026 (Item 8.01) to announce a company press release titled “BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs.” The press release, attached as Exhibit 99.1 to the 8-K, describes new clinical data that the company says advance its three RAS and PI3Kα oncology programs.

Key Details

• Filing date: January 7, 2026 (Form 8-K, Item 8.01).
• Press release title: “BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs.”
• The announcement concerns clinical data for three programs focused on RAS and PI3Kα targets.
• The full press release is attached as Exhibit 99.1 to the 8-K.

Why It Matters
Clinical data updates are primary drivers of value for oncology biotech companies. This 8-K informs investors that BridgeBio Oncology Therapeutics has released new clinical information about core RAS and PI3Kα programs—information that can affect development timelines, partnership interest, and investor expectations. Investors should read the attached press release (Exhibit 99.1) for the specific data and any disclosed next steps or timelines.